Introduction {#Sec1}
============

Mast cells (MCs, Fig. [1](#Fig1){ref-type="fig"}) are immune cells of hematopoietic origin found in all human tissues, especially at the environmental interfaces. They act as both effector and regulatory cells and play a central role in adaptive and innate immunity (Anand et al. [@CR17]; Gri et al. [@CR84]). Their important role in immunological as well as non-immunological processes is reflected by the large number of mediators (\>200) including pre-stored ones such as histamine and tryptase as well as numerous mediators synthesized de novo in response to allergic or non-immune triggers such as chemokines and cytokines, by which MCs may influence other cells (Lundequist and Pejler [@CR144]; Ibelgaufts [@CR104]). Their evolved arrays of sensory and response mechanisms engender diverse havoc when MC dysfunction emerges.Fig. 1May-Grünwald/Giemsa stain of a resting human mast cell and a mast cell following activation-induced degranulation. Note the loss of granule staining. Mast cells obtained from the human bone marrow, magnification 1000×

The umbrella term *mast cell activation disease* (MCAD; Akin et al. [@CR13]) comprises the full spectrum of primary systemic MC disease, i.e., *systemic mastocytosis* (SM) which is further divided into several subtypes (Valent et al. [@CR228]; Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}), primary *MC activation syndrome* (MCAS; Table [3](#Tab3){ref-type="table"}; Molderings et al. [@CR160]; Hamilton et al. [@CR93]; Valent et al. [@CR230]), and *MC leukemia* (MCL). Pathogenetically, MCAD denotes a group of polygenic MC disorders (Molderings [@CR156], [@CR157]) characterized by aberrant release of variable subsets of MC mediators and also an accumulation of either morphologically altered and immunohistochemically identifiable mutated MCs due to MC proliferation (SM and MCL) or morphologically ordinary MCs due to decreased apoptosis (MCAS; Kohno et al. [@CR124]; Aichberger et al. [@CR11]; Karlberg et al. [@CR111]). According to recent molecular genetic findings (Molderings [@CR156], [@CR157]; Haenisch et al. [@CR90]; Lasho et al. [@CR135]), the subclasses and clinical subtypes of MCAD do not represent distinct disease entities but should be more accurately regarded as variable presentations of a common generic state of MC dysfunction (Molderings et al. [@CR158], [@CR159]; Hermine et al. [@CR99]; Akin et al. [@CR13]). Due to both the widespread distribution of MCs and the great heterogeneity of aberrant mediator expression patterns, symptoms can occur in virtually all organs and tissues; hence, the clinical presentation of MCAD is very diverse, sometimes to the even-further-confounding point of presenting opposite abnormalities in different patients (or even in the same patient at different times, or in different sites in the same patient at the same time). While the prevalence of SM in Europeans ranges between 0.3 and 13 per 100,000 (Haenisch et al. [@CR89]; Cohen et al. [@CR50]; van Doormaal et al. [@CR232]), the prevalence of MCAS may be as high as 17 % (in Germany; Molderings et al. [@CR162], [@CR163]).Table 1WHO 2008 diagnostic criteria for systemic mastocytosis (Valent et al. [@CR227])Major criterion:1. Multifocal, dense aggregates of MCs (15 or more) in sections of the bone marrow or other extracutaneous tissues and confirmed by tryptase immunohistochemistry or other special stains\
Minor criteria:\
1. Atypical or spindled appearance of at least 25 % of the MCs in the diagnostic biopsy\
2. Expression of CD2 and/or CD25 by MCs in the marrow, blood, or extracutaneous organs\
3. KIT codon 816 mutation in the marrow, blood, or extracutaneous organs\
4. Persistent elevation of serum total tryptase \>20 ng/mlDiagnosis of SM made by either (1) the major criterion plus any one of the minor criteria or (2) any three minor criteriaTable 2Classification of systemic mastocytosis (modified form Valent et al. [@CR228])Categories of systemic mastocytosis (SM)SubtypesIndolent systemic mastocytosis• Smoldering systemic mastocytosis\
• Isolated bone marrow mastocytosis\
• Well-differentiated systemic mastocytosisAggressive systemic mastocytosis (ASM)• ASM in transformationSystemic mastocytosis with an associated clonal hematological non-mast cell lineage disease• SM-acute myeloid leukemia\
• SM-myelodysplastic syndrome\
• SM-myeloproliferative neoplasm\
• SM-chronic myelomonocytic leukemia\
• SM-chronic eosinophilic leukemia\
• SM-non-Hodgkin lymphoma\
• SM-multiple myelomaTable 3Current provisional criteria to define *mast cell activation syndrome* (MCAS; modified from Afrin and Molderings [@CR8])Major criterionConstellation of clinical complaints attributable to pathologically increased mast cell activity (mast cell mediator release syndrome)Minor criteria1.Focal or disseminated increased number of mast cells in marrow and/or extracutaneous organ(s) (e.g., gastrointestinal tract biopsies; CD117-, tryptase-, and CD25-stained)2.Abnormal spindle-shaped morphology in \>25 % of mast cells in marrow or other extracutaneous organ(s)3.Abnormal mast cell expression of CD2 and/or CD25 (i.e., co-expression of CD117/CD25 or CD117/CD2)4.Detection of genetic changes in mast cells from the blood, bone marrow, or extracutaneous organs for which an impact on the state of activity of affected mast cells in terms of an increased activity has been proven5.Evidence (typically from body fluids such as whole blood, serum, plasma, or urine) of above-normal levels of mast cell mediators including:•Tryptase in the blood•Histamine or its metabolites (e.g., *N*-methylhistamine) in the urine•Heparin in the blood•Chromogranin A in the blood (potential confounders of cardiac or renal failure, neuroendocrine tumors, or recent proton pump inhibitor use were excluded)•Other relatively mast cell-specific mediators (e.g., eicosanoids including prostaglandin PGD~2~, its metabolite 11-β-PGF~2α~, or leukotriene E4)6.Symptomatic response to inhibitors of mast cell activation or mast cell mediator production or action (e.g., histamine H~1~ and/or H~2~ receptor antagonists, cromolyn)Diagnosis of MCAS made by either (1) the major criterion plus any one of the minor criteria or (2) any three minor criteria

This review focuses on the current state of drug therapy in SM and MCAS and describes perspectives of promising new approaches for drug treatment. Compounds in various stages of preclinical and clinical development are summarized in tables. We first describe drugs that are currently available and either are used on a regular basis in MCAD therapy or have been used successfully in single MCAD cases. In this context, it should be noted that there is no official guideline for treatment of MCAD.

Treatment options {#Sec2}
=================

Due to its genetic roots, MCAD generally is regarded as incurable. Recent mutational studies revealed that each patient has an individual pattern of genetic and epigenetic alterations which may affect the intracellular signal transduction pathways and receptive sites involved in sensory perception. As a consequence, mediator formation and release as well as inhibition of apoptosis and/or increase in proliferation are determined by individual genetic and epigenetic conditions (Fig. [2](#Fig2){ref-type="fig"}) and represent potential targets for therapy. Hence, there is need of highly personalized therapy for the disease. Unfortunately (with regard to easy detection), most genetic alterations (with a few exceptions such as certain mutations in tyrosine kinase KIT, e.g., KIT^D816V^) do not alter the morphology and immunohistochemistry of the surface of the affected MCs. Thus, in most cases except for patients with the reliably identifiable D816V mutation, it cannot be decided by simple tests whether MCs found in biopsies are genetically altered MCs or physiological MCs.Fig. 2Scheme of conditions responsible in MCAD for the development of individual phenotypes

First-line treatment options {#Sec3}
----------------------------

Step 1 in managing most situations of inappropriate MC activation is identifying the individual patient's unique triggers (chemical, physical, or otherwise) as precisely as possible and then desensitizing when possible (in truth, rarely) and otherwise practicing avoidance. With respect to drug treatment, only a few clinical therapeutic trials have been conducted in SM (midostaurin, cladribine, masitinib; Table [4](#Tab4){ref-type="table"}), and there have been no therapeutic trials in MCAS yet. Most information about therapeutic effectiveness in MCAD has been found in small case series (Table [4](#Tab4){ref-type="table"}) and single case reports, perhaps unsurprising given the mutational heterogeneity of the disease and thus the heterogeneity of its patterns of clinical presentation and therapeutic responsiveness. Therefore, in the future, it may be helpful to establish an international patient registry in partnership with existing registries so that issues related to molecular and clinical MCAD phenotypes can be adequately addressed. As the primary feature of MCAD is inappropriate MC activation (Molderings et al. [@CR160], [@CR161]; Pardanani [@CR181]; Cardet et al. [@CR40]), mainstays of first-line management are identification and avoidance of triggers plus therapies to control MC mediator production (both primary as well as secondary/reactive; Table [5](#Tab5){ref-type="table"}) as well as their action (Table [6](#Tab6){ref-type="table"}).Table 4Case series and clinical therapeutic trials in systemic mastocytosis and mast cell activation syndromeCompoundNumber of patients included in the study or case seriesReferencesH~1~-antihistamines Rupatadine30Siebenhaar et al. [@CR207] Azelastine vs. chlorpheniramine15Friedman et al. [@CR73] Ketotifen vs. hydroxyzine8Kettelhut et al. [@CR117] Chlorpheniramine plus cimetidine8Frieri et al. [@CR74] Continuous diphenhydramine infusion10Afrin [@CR7] ^a^Mast cell stabilizer Cromoglicic acid (cromolyn)5Soter et al. [@CR210]11Horan et al. [@CR103]4Mallet et al. [@CR146]8Frieri et al. [@CR74]2Welch et al. [@CR236]2Zachariae et al. [@CR246] Tranilast2Katoh et al. [@CR113]Kinase inhibitors Imatinib (STI571)14Droogendijk et al. [@CR57]20Vega-Ruiz et al. [@CR233]22Lim et al. [@CR140]17Pagano et al. [@CR176]12Pardanani et al. [@CR182]5Heinrich et al. [@CR97]3Hennessy et al. [@CR98] Nilotinib (AMN107)61Hochhaus et al. [@CR101] Dasatinib (BMS-354825)33Verstovsek et al. [@CR234]4Purtill et al. [@CR190] Midostaurin (PKC412)9Papayannidis et al. [@CR180]11Knapper et al. [@CR122]22Chandesris et al. [@CR45]89Gotlib et al. [@CR83]14Strati et al. [@CR213] Masitinib25Paul et al. [@CR186]Cytostatic agents Hydroxyurea26Lim et al. [@CR140]5Afrin [@CR6] ^a^ Cladribine (2-chlorodeoxyadenosine)22Lim et al. [@CR140]10Kluin-Nelemans et al. [@CR120]4Pardanani et al. [@CR183]3Pagano et al. [@CR176]68Barete et al. [@CR24]Immunomodulation Interferon-α20Casassus et al. [@CR42]5Hauswirth et al. [@CR96]10Laroche et al. [@CR133]40Lim et al. [@CR140]8Pagano et al. [@CR176]6Giraldo Castellano et al. [@CR79]9Hennessy et al. [@CR98]3Worobec et al. [@CR240] Thalidomide16Gruson et al. [@CR86]IgE antibody Omalizumab4Molderings et al. [@CR161] ^a^2Carter et al. [@CR41]2Lieberoth and Thomsen [@CR139]ß-Sympathomimetics Isoprenaline, terbutaline5van Doormaal et al. [@CR231]Cyclooxygenase inhibitor Acetylsalicylic acid4Butterfield and Weiler [@CR38]20Butterfield [@CR36]^a^It indicates clinical trials performed with patients with mast cell activation syndromeTable 5First-line drugs which can potentially be used in the treatment of mast cell (MC) activation disease and their target location and mechanisms of actionTarget location/mechanisms of actionGrowth inhibitionDecrease of mediator releaseTo relieve symptomsReferencesFirst-line drugs H~1~-antihistamines (preferably of the second and third generations)Block mutual activation of mast cells via H~1~-histamine receptors; antagonize H~1~-histamine receptor-mediated symptomsXXChurch and Gradidge [@CR47]\
Valent et al. [@CR228]R\
Picard et al. [@CR189]R\
Nurmatov et al. [@CR172]\
Siebenhaar et al. [@CR207]\
Escribano et al. [@CR65]R H~2~-antihistaminesBlock mutual activation of mast cells via H~2~-histamine receptors; antagonize H~2~-histamine receptor-mediated symptomsXXValent et al. [@CR228]R\
Escribano et al. [@CR65]R Cromoglicic acid (also known as cromolyn)GPR35; modulation of chloride currentXXSoter et al. [@CR210]\
Valent et al. [@CR228]R\
Yang et al. [@CR244]\
Edwards et al. [@CR61]\
Edwards and Hagberg [@CR60]\
Zhang et al. [@CR248]\
Escribano et al. [@CR65]R Vitamin CIncreased degradation of histamine; decrease of histamine formation by inhibition of histidine decarboxylaseXXHagel et al. [@CR91]\
Johnston et al. [@CR107]\
Uchida et al. [@CR224]\
Chatterjee et al. [@CR46]As a rule, these drugs should be used in combination to achieve a sufficient reduction of MC activity. All drugs should be tested for tolerance in a low single dose before therapeutic use, if their tolerance in the patient is not known from an earlier application. A precondition for therapeutic success is the avoidance of identifiable triggers of MC activation; in this context, parallel to the beginning of drug therapy, gluten, cow milk protein, and baker's yeast should be omitted from the diet for 3--4 weeks*R* review article (further references therein)Table 6Symptomatic treatment (orally as needed) in MCAD (modified from Molderings et al. [@CR164])Colitis ⇒ budesonide; for some days, prednisone \>20 mg/dayDiarrhea ⇒ c(h)olestyramine; nystatin; montelukast; 5-HT~3~ receptor inhibitors (e.g. ondansetron); incremental doses of acetylsalicylic acid (50--350 mg/day; extreme caution because of the possibility to induce mast cell degranulation); in steps test each drug for 5 days until improvement of diarrheaColicky abdominal pain due to distinct meteorism ⇒ metamizole; butylscopolamineAngioedema ⇒ tranexamic acid; icatibantNausea ⇒ dimenhydrinate; lorazepam; 5-HT~3~ receptor inhibitors; NK1 antagonists such as aprepitantRespiratory symptoms (mainly due to increased production of viscous mucus and obstruction with compulsive throat clearing) ⇒ leukotriene receptor blockers such as montelukast; if in a country available, leukotriene synthesis inhibitors such as zileuton; urgent: short-acting ß-sympathomimeticGastric complaints ⇒ proton-pump inhibitors (de-escalating dose-finding)Osteoporosis, osteolysis, bone pain ⇒ bisphosphonates (vitamin D plus calcium application is second-line treatment in MCAD patients because of limited reported success and an increased risk for developing kidney and ureter stones); calcitonin; teriparatide (with caution; cases of cholestatic liver failure due to this drug have been reported); anti-RANKL drugs such as denosumab (dental clearance is required prior to treatment with bisphosphonates and anti-RANKL therapies due to risk for potentially severely morbid osteonecrosis of the jaw in patients with poor dentition or recent invasive dental work)Non-cardiac chest pain ⇒ when needed, additional dose of a H~2~-histamine receptor antagonist; also, proton-pump inhibitors for proven gastroesophageal refluxTachycardia ⇒ AT~1~-receptor antagonists; ivabradineNeuropathic pain and paresthesia ⇒ α-lipoic acidItches ⇒ palmitoylethanolamine-containing care products; cromolyn-containing ointmentRheumatoid symptoms ⇒ COX2 inhibitors such as etoricoxib or celecoxib; paracetamolAnemia ⇒ in iron-deficiency anemia, iron supplementation (whether oral or parenteral) must be given cautiously due to risk for potentially intense mast cell activation; alternatively, red blood cell transfusion should be consideredInterstitial cystitis ⇒ pentosan, amphetaminesSleep-onset insomnia/sleep-maintenance insomnia ⇒ triazolamConjunctivitis ⇒ exclusion of a secondary disease; otherwise preservative-free eye drops with H~1~-antihistamine, cromolyn, ketotifen, or glucocorticoid for brief coursesHypercholesterolemia ⇒ (probably due to inhibition of transport into the cells, thus independent of diet) \>300 mg/dL therapeutic trial with HMG-CoA reductase inhibitor atorvastatin

Subordinate therapeutic options {#Sec4}
-------------------------------

### Continuous diphenhydramine infusion {#Sec5}

Occasional patients suffer nearly continuous anaphylactoid and/or dysautonomic states poorly controlled by intermittently dosed epinephrine, antihistamines, and steroids. As discussed in more detail below, some such patients are particularly triggered by a wide range of medication excipients, making it challenging for them to tolerate trials of any adulterated (non-pure) medications, and yet some modicum of stability is required to pursue medication trials in such patients. Diphenhydramine is a well-tolerated histamine H~1~ receptor blocker (that among other non-threatening adverse affects can cause dizziness and an increase in appetite) which can quickly suppress MC activation and is used to treat allergic reactions and anaphylaxis. However, its half-life is as short as 1 h ([www.drugbank.ca/drugs/DB01075](http://www.drugbank.ca/drugs/DB01075)). Intermittently dosed, though, its initial therapeutic serum level rapidly declines to subtherapeutic levels and the patient seesaws into yet another flare. The safety of continuous diphenhydramine infusion was established in trials of the "BAD" regimen (diphenhydramine \[Benadryl\], lorazepam \[Ativan\], and dexamethasone) in refractory chemotherapy-induced emesis in adult and pediatric patients (Dix et al. [@CR56]; Jones et al. [@CR109]). In a small series of ten MCAS patients suffering almost continuous anaphylactoid/dysautonomic flares, continuous diphenhydramine infusion at 10--14.5 mg/h appeared effective in most patients at dramatically reducing flare rates and appeared safely sustainable at stable dosing for at least 21 months (Afrin [@CR7]). Stabilization has enabled successful trials of other helpful medications, but no patient has yet successfully stopped continuous diphenhydramine infusion.

### Acute and chronic immunosuppressive therapies {#Sec6}

Though typically not first-line, acute and chronic immunosuppressive therapies can be considered (Fig. [3](#Fig3){ref-type="fig"}; Table [7](#Tab7){ref-type="table"}) and may be particularly appropriate for patients possibly manifesting an autoimmune component of the disease as might be suggested by the presence, for example, of anti-IgE or anti-IgE-receptor antibodies. Glucocorticoids may exert beneficial effects in MCAD, including a decrease in production of stem cell factor (SCF, and possibly other cytokines) and a decrease in MC activation, by various mechanisms which have been extensively reviewed by Oppong et al. [@CR173]. Glucocorticoids at doses \>20 mg prednisone equivalent per day are frequently needed to effectively control otherwise refractory acute (and chronic) symptoms. Their chronic toxicity profile is disadvantageous for long-term use, but such toxicities have to be accepted in some cases. The influence of azathioprine, methotrexate, ciclosporine, hydroxyurea, and tamoxifen on MC activity can vary from no to moderate effect depending on individual disease factors. As in therapy of rheumatoid arthritis, azathioprine and methotrexate can be used in daily doses lower than those used in cancer or immunosuppressive post-transplant therapy. Effective MCAD therapy with ciclosporine requires doses as high as those used in transplantation medicine (M. Raithel, personal communication). Methotrexate has to be administered parenterally to be effective (unpublished observation, G.J. Molderings), and in the risk-benefit analysis, a possible non-immunologic histamine release from MCs (Estévez et al. [@CR67]) has to be considered. Hence, use of the compound should be limited to MCAD with methotrexate-sensitive comorbidities (e.g., rheumatoid arthritis and vasculitis).Fig. 3Suggested treatment options for mast cell activation disease. All drugs should be tested for tolerance in a low single dose before therapeutic use, if their tolerance in the patient is not known from an earlier application. For further details of indication, see textTable 7Second- and third-line drugs which can potentially be used in the treatment of mast cell activation disease and their target location and mechanisms of actionTarget location/mechanisms of actionGrowth inhibitionDecrease of mediator releaseTo relieve symptomsReferencesSecond-line drugsImmunosuppressive drugs AzathioprineMultiple targetsXXNolte and Stahl Skov [@CR171], Own unpublished data CiclosporineCalcineurin inhibitorXXKurosawa et al. [@CR129], Broyd et al. [@CR34], Trojan and Khan [@CR222], Own unpublished data GlucocorticoidsMultiple targets(X)XXZen et al. [@CR247]R HydroxyureaMultiple targetsXXLim et al. [@CR140], Afrin [@CR6] TamoxifenPrecise mechanism of action in MCAD unknownXXIn single casesButterfield and Chen [@CR37], Duffy et al. [@CR59]; MethotrexateMultiple targets?XSagi et al. [@CR201], Vrugt et al. [@CR235]Third-line drugs OmalizumabAnti-IgE antibodyXMolderings et al. [@CR161]\
Bell and Jackson [@CR25]; Kibsgaard et al. [@CR118]\
Kontou-Fili et al. [@CR125] Etoricoxib\
 Acetylsalicylic acidCOX-inhibitorsXButterfield and Weiler [@CR38]\
Breslow et al. [@CR32]\
Butterfield [@CR36] MontelukastAntagonist at cys-LT~1~ receptorsXTolar et al. [@CR220]\
Cikler et al. [@CR48]\
Breslow et al. [@CR32]\
Turner et al. [@CR223] Zileuton5-Lipoxygenase inhibitorXRodriguez et al. [@CR198]*R* review article (further references therein)

Recently, the humanized anti-IgE murine monoclonal antibody omalizumab has been described in multiple case reports as safe and effective in MCAD (e.g., Molderings et al. [@CR161]; Kontou-Fili et al. [@CR125]; Bell and Jackson [@CR25]; Kibsgaard et al. [@CR118]), though a definitive trial has yet to be conducted. Since treatment with omalizumab has an acceptable risk-benefit profile, it should be considered in cases of MCAD resistant to at least a few lines of therapy. The drug's expense likely consigns it to third-line (or later) treatment (Table [7](#Tab7){ref-type="table"}). If elevated prostaglandin levels induce symptoms such as persistent flushing, inhibition of cyclooxygenases by incremental doses of acetylsalicylic acid (ASA; 50--350 mg/day) may be used with extreme caution, since ASA can induce MC degranulation probably due its chemical property as an organic acid. The leukotriene antagonist montelukast (possibly more effective at twice-daily dosing; personal observation, L.B. Afrin) and the 5-lipoxygenase inhibitor zileuton may be useful adjuvants in people with MCAD, particularly in those with refractory gastrointestinal and urinary symptoms (Tolar et al. [@CR220]; Turner et al. [@CR223]; Akhavein et al. [@CR12]).

Studies of kinase inhibitors, both on-market (e.g., imatinib, nilotinib, dasatinib) and experimental (e.g., midostaurin, masitinib), have yielded variable responses in SM ranging from no response to partial or even complete responses (Fig. [3](#Fig3){ref-type="fig"}; Table [8](#Tab8){ref-type="table"}). As with all drugs used in therapy of MCAD, their therapeutic success seems to be strongly dependent on the individual patient, again underscoring the observed mutational heterogeneity of the disease. In formal studies in SM patients, although some kinase inhibitors reduced MC burden as reflected by histological normalization in bone marrow and improved laboratory surrogate markers (e.g., tryptase level in blood), at best only partial improvement of mediator-related symptoms was achieved (Droogendijk et al. [@CR57]; Gotlib et al. [@CR82]; Verstovsek et al. [@CR234]; Vega-Ruiz et al. [@CR233]). There has been repeated suggestion that symptoms in MCAD may be due more to mediator release from normal MCs secondarily activated by pathologically overactive, mutated MCs (Galli and Costa [@CR77]; Rosen and Goetzl [@CR199]; Boyce [@CR31]; Kaneko et al. [@CR110]; Fig. [2](#Fig2){ref-type="fig"} in Molderings et al. [@CR164]), helping to explain why intensity and pattern of symptoms do not correlate with degree of MC proliferation and infiltration (Topar et al. [@CR221]; Hermine et al. [@CR99]; Broesby-Olsen et al. [@CR33]; Erben et al. [@CR64]; Quintás-Cardama et al. [@CR192]). Distinction in pathways in the MC which promote MC proliferation vs. mediator production/release may explain why kinase inhibitors reduce MC burdens and MC-driven symptoms to different degrees (Droogendijk et al. [@CR57]; Gotlib et al. [@CR82]; Verstovsek et al. [@CR234]; Vega-Ruiz et al. [@CR233]; Table [8](#Tab8){ref-type="table"}). However, in some case reports, kinase inhibitors have been significantly effective at relieving symptoms. Thus, in spite of potential serious adverse effects of these drugs, a therapeutic trial may be justified in individual cases at an early stage. Partial and complete responses have been reported with some of these agents in MCAS too (e.g., Afrin [@CR3], [@CR4], [@CR5], [@CR7]; Afrin et al. [@CR9]). Dosing of the kinase inhibitors in the individual often is considerably lower than how such drugs are dosed for other applications (e.g., imatinib, sunitinib; Afrin et al. [@CR9]). Possibly due to the causative mutations in multiple genes leading to simultaneous activation of multiple intracellular pathways, multitargeted kinase inhibitors such as midostaurin and sunitinib may be more effective than drugs which selectively downregulate only one intracellular pathway.Table 8Kinase inhibitors which can potentially be used as fourth-line drugs in the treatment of mast cell activation disease and their target location and mechanisms of actionTarget location/mechanisms of actionGrowth inhibitionDecrease of mediator releaseTo relieve symptomsReferencesFourth-line drugsInhibitors of tyrosine kinases and other kinases ImatinibKIT (excluding D816X), PDGFR, Bcr-Abl, Arg/Abl2, DDR-1X(X)XPardanani et al. [@CR182]\
Droogendijk et al. [@CR57]\
Lim et al. [@CR140]\
Vega-Ruiz et al. [@CR233]\
Aman et al. [@CR16]\
Vaali et al. [@CR226]\
Quintás-Cardama et al. [@CR191]R\
Marton et al. [@CR149] NilotinibKIT, PDGFR, Bcr-AblX(X)Hochhaus et al. [@CR100]\
Quintás-Cardama et al. [@CR191]R\
Hochhaus et al. [@CR101]\
El-Agamy [@CR62] DasatinibKIT, BCR-ABL1, Lyn, Btk, TecX(X)Verstovsek et al. [@CR234]\
Hantschel et al. [@CR94]\
Gleixner et al. [@CR80]\
Quintás-Cardama et al. [@CR191]R SunitinibVEGFR, PDGFR, KIT, FLT3, RET, CSF1R, SRC,\
313 potential kinase targetsXXXAfrin et al. [@CR9]\
Yamaki and Yoshino [@CR243]\
Papaetis and Syrigos [@CR179]\
Bairlein [@CR23] MasitinibKIT, PDGFRα, Lck, LYN, FGFR3, FAKXXMarech et al. [@CR147]\
Moussy and Kinet [@CR167]\
Paul et al. [@CR186]\
Quintás-Cardama et al. [@CR191]R MidostaurinPKC, FLT3, KIT, PDGFR, VEGFR2XXXGotlib et al. [@CR83]\
Papayannidis et al. [@CR180]\
Knapper et al. [@CR122]\
Quintás-Cardama et al. [@CR191]R PonatinibBcr-Abl, KIT, FLT3, FGFR1, PDGFRα, LynXJin et al. [@CR106]\
Gleixner et al. [@CR81] BafetinibKIT (excluding D816X), Abl, LynXPeter et al. [@CR187] BosutinibLyn, BtkXIn ASM patients ineffectiveGleixner et al. [@CR80]\
Randall et al. [@CR194]*R* review article (further references therein)

In the mastocytosis patient with significant MC burden and/or an aggressive clinical course, cytoreductive drugs are prescribed (Lim et al. [@CR140]; Valent et al. [@CR229]). Unfortunately, effective cytoreductive therapies in SM presently are few in number and typically offer only modest response rates, qualities, and durations. Cytoreductive options include interferon-α and 2-chlorodeoxyadenosine (cladribine, 2-CdA; Fig. [3](#Fig3){ref-type="fig"} and Table [9](#Tab9){ref-type="table"}). Interferon-α is frequently combined with prednisone and is commonly used as cytoreductive therapy for aggressive SM. It ameliorates mastocytosis-related organopathy in a proportion of cases but can be associated with considerable adverse effects (e.g., flu-like symptoms, myelosuppression, depression, hypothyroidism), which may limit its use in MCAD (Simon et al. [@CR209]; Butterfield [@CR35]). PEGylated interferon-α has been shown to be as efficacious as and less toxic than the non-PEGylated form in some myeloproliferative neoplasms, but it has not been specifically studied in MCAD. 2-Chlorodeoxyadenosine is generally reserved for last-choice treatment of patients with aggressive SM who are either refractory or intolerant to interferon-α. Potential toxicities of 2-CdA include significant and potentially prolonged myelosuppression and lymphopenia with increased risk for opportunistic infections.Table 9Last-choice drugs which can potentially be used in the treatment of mast cell activation disease and their target location and mechanisms of action. R-review article (further references therein)Target location/mechanisms of actionGrowth inhibitionDecrease of mediator releaseTo relieve symptomsReferencesLast-choice drugs Interferon-αMultiple targetsX(X)Simon et al. [@CR209]\
Casassus et al. [@CR42]\
Hauswirth et al. [@CR96]\
Butterfield et al. [@CR39]\
Butterfield [@CR35]R\
Yoshida et al. [@CR245]\
Lim et al. [@CR140]\
Quintás-Cardama et al. [@CR191]R CladribineNucleoside analogXXXTefferi et al. [@CR219]\
Kluin-Nelemans et al. [@CR120]\
Pardanani et al. [@CR183]\
Lim et al. [@CR140]\
Böhm et al. [@CR29]\
Radojković et al. [@CR193]\
Quintás-Cardama et al. [@CR191]R\
Lock et al. [@CR143]\
Barete et al. [@CR24]

### Last resorts {#Sec7}

Polychemotherapy, including intensive induction regimens of the kind used in treating acute myeloid leukemia, as well as high-dose therapy with stem cell rescue, are approaches restricted to rare, selected patients. Allogeneic stem cell transplantation sometimes yields remissions in mastocytosis long thought impermanent (Spyridonidis et al. [@CR212]; Nakamura et al. [@CR170]; Bae et al. [@CR21]; Gromke et al. [@CR85]), though recent data may offer new hope (Ustun et al. [@CR225]).

Investigational drugs {#Sec8}
---------------------

There are several drugs approved for indications other than MCAD which already have been successfully used in isolated cases with MCAD (Table [10](#Tab10){ref-type="table"}). In cases of unsuccessful first- to fourth-line therapy, these compounds may be considered as treatment options.Table 10Drugs successfully (or not) used off-label to treat isolated cases of mast cell activation diseaseTarget location/mechanisms of actionGrowth inhibitionDecrease of mediator releaseTo relieve symptomsReferencesInvestigational drugs ThalidomidePrecise mechanism of action unknownXDamaj et al. [@CR54]\
Gruson et al. [@CR86] LenalidomideNo effectKluin-Nelemans et al. [@CR121] Flavonoids (e.g., luteolin, quercetin, genistein)MultipleX(X)(X)Alexandrakis et al. [@CR15]\
Kempuraj et al. [@CR116]\
Min et al. [@CR155]\
Finn and Walsh [@CR71]R\
Weng et al. [@CR238]\
Lee et al. [@CR138]\
Weng et al. [@CR239] MiltefosineRaft modulatorX(X)Weller et al. [@CR237]\
Maurer et al. [@CR152]R MepolizumabIL-5 antibodyXOtani et al. [@CR174] RituximabCD20 antibodyXBorzutzky et al. [@CR30] RuxolitinibJAKXXYacoub and Prochaska [@CR241]\
Kvasnicka et al. [@CR131] CannabinoidsAgonists at the cannabinoid receptorsXDe Filippis et al. [@CR55]\
Frenkel et al. [@CR72]\
Own unpublished experiences Methylene blueGuanylyl cyclase inhibitorAnaphylaxis treatmentRodrigues et al. [@CR197]\
Evora and Simon [@CR69]R PimecrolimusCalcineurin inhibitorXCutaneous symptoms; (mice)Ma et al. [@CR145]\
Correia et al. [@CR53] EverolimusmTORno effectParikh et al. [@CR184] RibavirinPossibly suppression of activated retroviral elements in the genome which may be involved in the development of the somatic mutations in KIT and other proteinsXXMarquardt et al. [@CR148]\
Molderings [@CR157]\
Own unpublished experiences*R* review article (further references therein)

A variety of drugs have been shown to inhibit MC growth, to decrease MC mediator release, and/or to relieve mediator-induced symptoms in in vitro and in vivo animal models (Table [11](#Tab11){ref-type="table"}). Some of these drugs are approved for certain indications (such as ambroxol, statins, mefloquine, and ruxolitinib) and, thus, may be used (if accessible given financial considerations for some agents) if MCAD patients suffer from both the disorder of indication (e.g., hypercholesterolemia---statins, mucous congestion---ambroxol, polycythemia vera---ruxolitinib) and MCAD. An important question is what the role of the other compounds without approved indications should be in clinical practice. There are several challenges that may hamper the clinical introduction of novel targeted therapies in general. Some of these challenges include inherent problems in the translation of preclinical findings to the clinic, the presence of multiple coactive deregulated pathways in the disease, and questions related to the optimal design of clinical trials (e.g., eligibility criteria and endpoints). In particular, the testing of novel targeted treatment in an isolated fashion may be problematic and may in fact underestimate the effectiveness of these novel compounds. It is reasonable to assume that combination therapy will be the key to target parallel critical pathways.Table 11Investigational drugs which might have activity against mast cell activation disease since they induce apoptosis of mast cells and/or suppress mast cell mediator release in vitro and/or in vivoTarget location/mechanisms of actionGrowth inhibitionDecrease of mediator releaseTo relieve symptomsInvestigated in vitroInvestigated in vivoReferencesInvestigational drugs ABT-737 {(*R*)-4-(3-dimethylamino-1-phenylsulfanylmethyl-propylamino)-*N*-{4-\[4-(4′-chloro-biphenyl-2-ylmethyl)-piperazin-1-yl\]-benzoyl}-3-nitro-benzenesulfonamide)}BH3 mimeticXMurine BMMC, human cord blood-derived MCs, C57 MC line, MC/9 MC lineMiceKarlberg et al. [@CR112] 17-Allylamino-17-demethoxygeldanamycin,\
 Ganetespib (STA-9090)Binding to heat shock protein 90XHMC-1, canine BMMC, C2 MC line, BR canine mastocytoma cell linesFumo et al. [@CR76]\
Lin et al. [@CR141] AmbroxolMultipleXHuman MCsGibbs et al. [@CR78] Amitriptyline, clomipramine, maprotilineYet to be defined in MCADXMale Wistar ratsGurgel et al. [@CR87]\
Clemons et al. [@CR49] BenzodiazepinesYet to be defined(X)XXMolderings et al. [@CR163]; Dueñas-Laita et al. [@CR58]; Bidri et al. [@CR27]; Fujimoto et al. [@CR75]; Suzuki-Nishimura et al. [@CR214]; Hoffmann et al. [@CR102] BI 2536 {(*R*)-4-(8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-ylamino)-3-methoxy-*N*-(1-methylpiperidin-4-yl)benzamide}Polo-like kinase-1XHMC-1, primary human neoplastic MCsPeter et al. [@CR188] BLU-285 (chemical structure not yet published)KITXHMC-1.2,\
P815 mouse mastosarcoma cellsEvans et al. [@CR68] Botulinum toxin ACleavage of the SNARE proteinsXXSD ratsPark [@CR185] ButaprostEP~2~ receptor agonistXHuman lung MCsKay et al. [@CR114] Cerivastatin, fluvastatin, atorvastatinUnknown in MCADXXPrimary human MCs, HMC-1, P815Krauth et al. [@CR126]\
Paez et al. [@CR175] Chemokine receptor antagonistsTargeting activating chemokine receptors expressed on MCsXMiceKoelink et al. [@CR123]R CinnamaldehydeSignaling molecules, e.g., ERK1/2, JNK, p38, AktXHuman MCs, RBL-2H3 cellsHagenlocher et al. [@CR92]\
Bibi et al. [@CR26]R Combined arginine and glutamineMultipleXHuman intestinal MCsLechowski et al. [@CR137] Coumarines (scopoletin)Yet to be defined in MCADXHMC-1Moon et al. [@CR165]\
Finn and Walsh [@CR71]R CRA1000 {*N-*ethyl-4-\[4-(3-fluorophenyl)-3,6-dihydro-2*H*-pyridin-1-yl\]-6-methyl-*N*-(2-methylsulfanyl-4-propan-2-ylphenyl)pyrimidin-2-amine}Non-peptidic corticotropin-releasing factor antagonistXMouse dermal MCsShimoda et al. [@CR205] CrenolanibFLT3XHMC-1, p815, MCs from SM patientsSchittenhelm et al. [@CR203] CurcuminMultipleXHMC-1, murine BMMCBALB/c miceBaek et al. [@CR22]\
Kinney et al. [@CR119] Demethylating agents (5-azacytidine, 5-aza-2′deoxycytidine)DNA methylationX(X)HMC-1Krug et al. [@CR128]\
Meeran et al. [@CR154]R EXEL-0862 (WO2004050681 A2)KIT, STAT3XHMC-1Pan et al. [@CR178] Fedratinib (TG101348)JAK2 inhibitionXHMC-1Lasho et al. [@CR134] GLC756 {(3R,4aR,10aR)-l,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-methyl-3-\[(2-pyridyl-thio) methyl\]-benzo \[gq\]uinolinehydrochloride)}Dopamine D~1~ and D~2~ receptor agonistXRBL-2H3 cellsLaengle et al. [@CR132] Gly-Phe-CHN~2~, PZ610, PZ709, PZ889 (chemical structures not yet published)Dipeptidylpeptidase-1 inhibitorsLAD2 MCEl-Feki et al. [@CR63] Histamine H~4~-receptor agonistHistamine H~4~-receptorXXHMC-1, murine MCsEx vivo guinea pig and murine heartsAldi et al. [@CR14] Histone deacetylase inhibitors: vorinostat, AR-42 {*N*-hydroxy-4-\[\[(2S)-3-methyl-2-phenylbutanoyl\]amino\]benzamide}Histone deacetylaseXHMC-1.2, primary human MCs, murine, and canine MCsMühlenberg et al. [@CR168]\
Hadzijusufovic et al. [@CR88]\
Meeran et al. [@CR154]R\
Abdulkadir et al. [@CR1]\
Lin et al. [@CR142] HypothemycinInhibition of KIT and BtkXHuman MCsMiceJensen et al. [@CR105] IMD-0354 {*N*-\[3,5-bis(trifluoromethyl)phenyl\]-5-chloro-2-hydroxybenzamide}NF-κB inhibitorXHMC-1Tanaka et al. [@CR216] JTE-052 {3-{(3R,4R)-4-methyl-3-\[methyl-(7*H*-pyrrolo\[2,3-d\]pyrimidin-4-yl)-amino\]-piperidin-1-yl}-3-oxo-propionitrile mono citrate}JAK1,2,3 inhibitor, Tyk2 inhibitorXHuman MCsDBA/1J mice, Lewis ratsTanimoto et al. [@CR218] MefloquinePermeabilization of secretory granulesXHuman and murine MCsPaivandy et al. [@CR177] Mylotarg (gemtuzumab ozogamicin)CD-33 targeting drugXHMC-1, human cord blood-derived MCsKrauth et al. [@CR127] NeramexanePossibly NMDA antagonistXHMC-1 cellsKurzen [@CR130] ObatoclaxBH3 mimeticXHMC-1, human neoplastic BMMCAichberger et al. [@CR11] ONO-4053 (chemical structure not yet published)Prostaglandin receptor DP1 antagonistXHuman BMMCYamaguchi et al. [@CR242] 8-OH-DPAT (7-(Dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol)5-HT~1A~ receptorNo effectXRitter et al. [@CR195] PalmitoylethanolamidePPAR-α, cannabinoid receptors, potassium channels, TRPV1Xrat peritoneal MCsFacci et al. [@CR70]\
Mattace Raso et al. [@CR151]R PD180970 {6-(2,6-dichlorophenyl)-2-(4-fluoro-3-methylanilino)-8-methylpyrido\[2,3-d\]pyrimidin-7-one}KIT, Bcr-Abl, PDGFRXHMC-1, P815 MCsCorbin et al. [@CR52] Phosphodiesterase inhibitorsPhosphodiesteraseXHuman lung MCs, rat MCsWistar ratsLau and Kam [@CR136]; Eskandari et al. [@CR66]\
Babaei and Bayat [@CR19] Phosphatidylethanolamine, phosphatidylserineCD300aXHuman cord blood-derived MCs, human lung MCs, murine BMMCBachelet et al. [@CR20]\
Simhadri et al. [@CR208] Prostaglandin D~2~ receptor antagonistsCRTH2XHarvima et al. [@CR95]R Proteases inhibitorsTryptase, chymase, cathepsins, carboxypeptidaseXHuman and murine MCsMiceCaughey [@CR43]R\
Harvima et al. [@CR95]R RapamycinmTOR pathway inhibitorXHMC-1Chan et al. [@CR44] RNAiRNA interference against *KIT* RNAXHMC-1Ruano et al. [@CR200] Rosiglitazone, pioglitazonePPARγXMurine BMMCTachibana et al. [@CR215] SiramesineSigma-2 receptor agonistXHuman and murine MCsSpirkoski et al. [@CR211] SitagliptinDipeptidylpeptidase-4 inhibitorXRat peritoneal MCsNader [@CR169] 1845 SomatostatinSomatostatin receptorsXWistar ratsTang et al. [@CR217] Syk kinase inhibitorsSyk kinaseXHuman, murine, and rat MCs; RBL-2H3Matsubara et al. [@CR150]\
Finn and Walsh [@CR71] Tandutinib (MLN518)KIT, STAT3XHMC-1, P815 MCsCorbin et al. [@CR52] TetracyclinesMultipleXXRat serosal MCs, HMC-1HumanSandler et al. [@CR202]\
Joks and Durkin [@CR108]R α-TocopherolMultipleXHMC-1Kempna et al. [@CR115]\
Ruano et al. [@CR200] TranilastYet to be definedX(X)Rat peritoneal MCRats; rabbitsAdachi et al. [@CR2]\
Cooper et al. [@CR51]\
Baba et al. [@CR18] Whi-P131 {4-\[(6,7-dimethoxyquinazolin-4-yl)amino\]phenol}JAK3/STAT pathway inhibitorXHMC-1Chan et al. [@CR44]\
Bibi et al. [@CR26]R*R* review article (further references therein), *MC* mast cell, *BMMC* bone marrow-derived mast cells

General considerations on drug treatment of MCAD {#Sec9}
------------------------------------------------

Although no biomarkers of symptomaticity or therapeutic response are yet validated, the tolerability and efficacy of most therapies tried in MCAD (starting, and escalating in dosage and composition, cautiously) become clinically evident within 1--2 months. Modest experiments with alternative dosages and/or dosing frequencies are not unreasonable. Therapies clearly shown clinically helpful should be continued; therapies not meeting this high bar should be halted to avoid the troublesome polypharmacy that can easily develop in such patients. With no predictors of response yet available, a cost-based approach to sequencing therapeutic trials in a given patient seems reasonable. It is not even clear yet that medications targeted at mediators found elevated in diagnostic testing (e.g., antihistamines in patients with elevated histamine, non-steroidal anti-inflammatory drugs in patients with elevated prostaglandins, leukotriene inhibitors in patients with elevated leukotrienes) are reliably effective, again perhaps unsurprising given the multitude of MC mediators and the complexity of the signaling networks dysregulated by the multiple mutations in MC regulatory elements present in most MCAD patients. Successful regimens appear highly personalized.

Multiple simultaneous (or nearly so) changes in the medication regimen are discouraged since such can confound identification of the specific therapy responsible for a given improvement (or deterioration). Ineffective or harmful agents should be stopped promptly. Prescribers should be aware that although rapid demonstration of intolerance of a new medication (or a new formulation of a previously well-tolerated medication) often suggests excipient reactivity as further discussed below, some active drug molecules themselves (e.g., cromolyn) sometimes cause an initial symptom flare which usually soon abates. Temporary waiver of gluten-, yeast-, and cow milk protein-containing foods during the initial 3--4 weeks of drug therapy can improve the response rate (Biesiekierski et al. [@CR28]; Rodrigo et al. [@CR196]; own unpublished experiences). When MCAD is suspected, therapies that strongly activate the immune system (e.g., vaccinations with live vaccines or autohemotherapy) must be given with caution (especially if similar therapies were previously already poorly tolerated), as such interventions sometimes dramatically worsen MCAD acutely and/or chronically.

Any drug can induce intolerance symptoms in the individual MCAD patient. In some MCAD patients, the disease creates such remarkable states of not only constitutive MC activation but also aberrant MC reactivity that such patients unfortunately experience a great propensity to react adversely to a wide variety of medication triggers. Those MCAD patients begin demonstrating (either acutely or subacutely) odd/unusual/weird/strange/bizarre/unexpected symptoms soon after beginning new medications. It is very important to note that such patients often demonstrate even a greater propensity to react to medication excipients (i.e., fillers, binders, dyes, preservatives) than to the active ingredients. When the patient tries one or more alternative formulations of a medication with the same active ingredient but sharing as few as possible (preferably none) of the excipients in the offending formulation, the patient may discover the medication to be at least tolerable and perhaps even quite effective. Furthermore, such a scenario obviously provides the patient (and physician and pharmacist) a great opportunity to identify one or more of the specific excipients which are triggering abnormal reactivity in the patient's dysfunctional MCs, and it is those specific excipients---not the medication as a whole---that should be added to the patient's allergy list and screened against all present medications being taken by the patient and against all future medications proposed for the patient. An MCAD patient's physician would be wise to not assume, just because an excipient is very widely used in many medication products and appears innocuous and well tolerated in the vast majority of patients, that the same excipient will necessarily be tolerated well in MCAD patients (unpublished observation of the authors). Sometimes the specificity of the reaction is quite extraordinary. For example, patients who react to wood-based microcrystalline cellulose might tolerate cotton-based microcrystalline cellulose without any difficulty at all, or vice versa. In some cases, the pharmacist is unable to identify alternative commercially available formulations sharing few to none of the excipients in the offending formulation, and in those cases, a compounding pharmacist may need to be engaged to identify/develop a custom-compounded formulation the patient can tolerate. (There can be geographic and financial challenges in accessing compounding pharmacies, though.) Occasionally, MCAD patients may be so remarkably reactive to such a wide range of excipients that they can only tolerate a given medication when provided as pure drug salt, reconstituted in water (without preservatives). Intolerance symptoms can be mediated by IgE antibodies, though this scenario appears to be rare since the symptoms are usually not ameliorated by the anti-IgE monoclonal antibody omalizumab (unpublished observation, G.J. Molderings). Alternatively, they may be mediated by IgG antibodies, raising the question of whether gamma globulin (if itself tolerable) might be a helpful adjunct therapy in such patients (perhaps by directly targeting the MC surface's IgG receptors or via indirect pathways). Recently, a MC-specific receptor termed MRGPRX2 has been identified which appears to be crucially involved in pseudo-allergic drug reactions (McNeil et al. [@CR153]; Seifert [@CR204]).

Drugs which should not be used in MCAD {#Sec10}
--------------------------------------

Several drugs have the ability to trigger MC mediator release. A compilation of drugs known to be associated with a high risk of release of mediators from MCs is given in Table [12](#Tab12){ref-type="table"}. However, there often are therapeutic alternatives to these drugs (Table [12](#Tab12){ref-type="table"}).Table 12Compilation of drugs associated with a high risk of release of mediators from mast cells and their therapeutic alternatives (compiled from Mousli et al. [@CR166]; Sido et al. [@CR206]; Afrin et al. [@CR10]; McNeil et al. [@CR153])Substance groupDrugs with proven or theoretical high risk of mast cell activationTherapeutic alternativesIntravenous narcoticsMethohexital\
Phenobarbital\
ThiopentalPropofol\
Ketamine\
Etomidate\
MidazolamMuscle relaxantsAtracurium\
Mivacurium\
RocuroniumCis-atracurium\
VecuroniumAntibioticsCefuroxim\
Gyrase inhibitors\
VancomycinRoxithromycinSelective dopamine- and norepinephrine reuptake inhibitorsBupropionAmitriptyline, doxepine, clomipramine, maprotilineSelective serotonin reuptake inhibitorsAllAnticonvulsive agentsCarbamazepine, topiramateClonazepamOpioid analgesicsmeperidine, morphine, codeineremifentanil, alfentanil, fentanyl, oxycodon, piritramidPeripheral-acting analgesicsAcidic non-steroidal anti-inflammatory drugs such as ASS or ibuprofenParacetamol, metamizolLocal anestheticsAmide-type: lidocaine\
articaine\
Ester-type: tetracaine,\
procaineprefer amide-Type, e.g., bupivacainePeptidergic drugsIcatibant, cetrorelix, sermorelin, octreotide, leuprolideX-ray contrast mediumIodinated contrast medium\
Gadolinium chelateNon-ionic contrast media: iohexol, iopamidol, iopromida, ioxilan, ioversol, idolatran, iodixanolPlasma substitutesHydroxyethyl starch\
GelatineAlbumin solution, 0.9 %-NaCl solution, Ringer's solutionCardiovascular drugsACE inhibitors\
ß-Adrenoceptor antagonistsSartans, calcium channel antagonists, ivabradine, and much else

Conclusions and future perspectives {#Sec11}
===================================

The therapeutic management of individuals with MCAD is complex and requires reviewing the entire spectrum of symptoms. The paucity of randomized, controlled studies makes treatment of refractory disease challenging and requires patience, persistence, and a methodical approach on the parts of both patient and managing provider(s). Delayed control of the symptoms may increase morbidity. Effective therapy often consists simply of antihistamines and MC-stabilizing compounds supplemented with medications targeted at specific symptoms and complications (Table [13](#Tab13){ref-type="table"}). Current treatment options for refractory disease are based mainly on observational studies and case reports. Until larger randomized, controlled trials become available to give more guidance on therapy for refractory disease, clinicians should use the available data in conjunction with their clinical expertise and the adverse effect profile of the available drugs to make treatment decisions. More research is certainly needed to better understand MCAD pathobiology, in particular to determine which deregulated genes contribute to a specific symptom or symptom cluster. The greatest challenge in translational research for the discovery of new rational therapies requires a highly interactive interdisciplinary approach engaging basic science labs and clinicians. Understanding of the key components might hasten the progress of novel treatment for all these devastating MCAD phenotypes.Table 13Schematic summary of selected potential targets of pharmacological interventions in MCADTargets of drugs located in the plasma membrane Histamine H~1~ receptorH~1~-antihistamines Histamine H~2~ receptorH~2~-antihistamines CB1/CB2 cannabinoid receptorsCannabinoids cysLTR1 leukotriene receptorCysLTR1 antagonists, e.g., montelukast ß-Adrenoceptorß-Sympathomimetics EP~2~ receptorEP~2~ receptor agonist, e.g., butaprost Chemokine receptorsChemokines FcεRIIgE antibody, e.g., omalizumab FcγRIIIIgG Siglec-8Siglec-8 ligand CD300aPhosphatidylethanolamine, phosphatidylserineTargetting released mast cell mediators TryptaseTryptase inhibitor, e.g., nafamostat ChymaseChymase inhibitor, e.g., BCEAB (4-\[1-\[bis-(4-methyl-pheny)-methyl\]-3-(2-ethoxy-benzyl)-4-oxo-azetidine-2-yloxy\]-benzoic acid) Cathepsin GCathepsin G inhibitor, e.g., RWJ355871 (β-ketophosphonate 1) TNFαInfliximab, adalimumab IL-4Pascolizumab IL-5e.g., mepolizumab IL-6e.g., sirukumab IL-17e.g., secukinumabIntracellular inhibition of mediator formation HistamineHistidine decarboxylase inhibition, e.g., by vitamin C Leukotrienes5-Lipoxygenase inhibitors, e.g., zileuton ProstaglandinsCyclooxygenase inhibitors, e.g., acetylsalicylic acid, etoricoxibInhibition of cytosolic pathways Signaling pathways containing protein kinasesInhibitors of protein kinases (see Table [8](#Tab8){ref-type="table"}) mTOR pathwaye.g., rapamycin, everolimus Apoptotic pathwaysStimulation of apoptosis by, e.g., ABT-737, obatoclaxIntranuclear targets Histone deacetylaseHistone deacetylase inhibitors, e.g., vorinostat DNA methylationDemethylating agents, e.g., 5-azacytidine, 5-aza-2′deoxycytidine DNANucleoside analog cladribine
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